Capstone Holding Corp. · NASDAQ:CAPS
Capstone — Capstone Therapeutics — Corporate Update (February 2016)
14 slides from Capstone's corporate update, Feb 11, 2016
Slide 1: Operating Update
Capstone Therapeutics (OTCQB: CAPS) Operating Update February 11, 2016 4:30 p.m. EST Conference Call Capstone
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation or otherwise getrinutable to Capstone regarding ¢ our ihe on inBGE provisions of th je je Act of 1995. These forward-looking rements involve risks and uncertainties that results to differ materially from predicted results. dis liscussed in our Fo
Slide 3: JV Milestones Over Last 15 Months
JV Milestones Over Last 15 Months 1a/ib/2 ini i Subjects) > Met All Study Objectives Powerful and Rapid Reduction in VLDL and Triglycerides A Hf Hf 14) ) matter Pot ential 21 Year Fresh Patent Life L dose = GRAS excipients — easy to manufacture IV. p gi Orphan Indications > Diabetic dyslipidemia y .
Slide 4: Fundraising Chronology
Fundraising Chronology June 2015 Announced Dismissal of 6 Year Qui Tam Lawsuit June 2015 Filed S-1 i i 10MM Sept 2015 gage Sept/Oct 2015 Marketing Meeting / Travel Nov 2015 i (Due Diligence) for Dec 2015 with CAPS Shareholder; 8-K Filed Jan 13, 2016 | i i Jan 29, 2016 CAPS Shareholder Notifies Decli
Slide 5: Capstone Assets: CAPS Shareholder Value Preservation Plan
Capstone Assets: CAPS Shareholder Value Preservation Plan > Cashand receivables > 60% Ownership in LipimetiX Development, Inc > Lipi (AEM-28-14 Program in HoFH, Hypertriglyceridemia, Diabetic Dyslipidemia) Premise: > F Action Plan: value hat potential value for benefit of C. > Tar; arget 12+ y furth
Slide 6: CAPS Shareholder Value Preservation Plan (Continued)
CAPS Shareholder Value Preservation Plan (Continued) Future Funding: > Stock price is so low that any fundraising in CAPS is extremely dilutive to SH — "mafbulencer! in stork market psd d mphasized = Pulled S-1 Filing » Raise New Funds in Lipimetix = Lipimetix raise is likely at higher valuation tha
Slide 7: AEM-28-14 Program Update
AEM-28-14 Program Update New Chimeric Peptides: AEM-28 Analogs: AEM-28-14 LipimetixX /University of Alabama > New IP ifyir d to. . i ication fil 2016. > Enhanced efnicacy = AEM- = Binds ue ws all classes of lipoproteins > ei safety and toleration anism of venous irritation identified * GRAS excipien
Slide 8: AEM-28-14: Preclinical Efficacy
AEM-28-14: Preclinical Efficacy Percentage of Baseline Plasma Cholesterol Null Mice (+ SEM) (Hyperbolic Curve Fit) ° 10 20 30 Dose (ug) lal AEM-28 iT imi I 28; 14 Virtually Capstone
Slide 9: Efficacy Data with new Chimeric Peptides
Efficacy Data with new Chimeric Peptides 120 AEM28-14 and AEM-28-02 vs. AEM-28 in 1200 5 1000 Cholesterol (mg/dl) 100 ug Injections 100 8 Percent Cholesterol g Time (hours) Sub Q vs. jectir AEM-28-14 In Apo E Null Mice —saline —P 100 —P 200 —sa 100 —sa 200 Baseline hour S hours 24 hours
Slide 10: AEM-28-14 Development Plan
AEM-28-14 Development Plan What Does Pharma Want To See? 1) Full Pre-IND Tox/PK Package 2) Full CMC Package 3) Phase 1a— Single Ascending Dose — Safety/Efficacy ) Phase 1b — Multiple Ascending Dose — Safety/Efficacy 5) Phase 2 = Multi-center, Multis dose in Subjects with Refractory Hypertriglyceride
Slide 11: Company Estimated AEM-28-14 Development Schedule
Company Estimated AEM-28-14 Development Schedule isiestone | ars azte jase jase Jamz jaa7 |asn7 |asn7 | ae cmc ——, Pre-Clinical LE IND/CTA | Phase 1a | Phase 1b fe Phase 2 —_—S ee] Esti Pr li al u t ida! 2 rata Lipimetix Deli ior AEM i = ig Capstone
Slide 12: AEM-28-14 Development Plan
AEM-28-14 Development Plan Plan Is To “Partner” Phase 2b/3 Trials Which Can Be Targeted To Multiple TG/Cholesterol Indications: <Orohan lndicati HoFH Vascular Diseases —| ket: Diabetic / Vascular Complications = Acute Coronary Syndrome > Dyslipidemia — large markets, extended treatment = Metabolic S
Slide 13: Summary
Summary > PRESENT FOCUS WILL BE RAISING NEW CAPITAL IN LIPIMETIX > LIPIMETIX IS ACTIVELY INVOLVED IN NOW (AMOUNT AND VALUATION TO BE DETERMINED BY MARKET) > AEM-28-14 Program Composition of Matter IP Through 2035 Unprecedented Efficacy / Increased Tolerability Subcutaneous Delivery Potential Risk-Mi
Slide 14: Capstone
CAPSTONE Capstone Therapeutics Corp. 1275 W. i Suit uite 104 Libim Eipime LipimetiX Development, Inc. Suite 2A Tempe, AZ 85281 OTCQB: CAPS Jock Holliman 602-286-5586 jholliman@capstonethx.com Natick, MA 01760 Dennis Goldberg, PhD. 508-651-371! dgoldberg@lipimetix.com Capstone
Capstone Therapeutics — Corporate Update (February 2016) on 6ix